Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -58.4%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $9M | $3M | $9M | $16M | $41M | — |
| Enterprise Value | $-51243622 | $-46088949 | $-3470071 | $-7172532 | $-16375048 | $-12241909 | — |
| P/E Ratio → | -0.18 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 2703.81 | — |
| P/B Ratio | 0.07 | 0.16 | 0.23 | 0.39 | 0.38 | 0.79 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | -812.77 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | -14.7% | — |
| Operating Margin | — | — | — | — | — | -29925.7% | — |
| Net Profit Margin | — | — | — | — | — | -14430.5% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -58.4% | -58.4% | -72.8% | -48.4% | -29.7% | -8.4% | -25.5% |
| ROA | -53.5% | -53.5% | -65.9% | -44.8% | -28.3% | -8.1% | -24.8% |
| ROIC | -395.0% | -395.0% | -142.4% | -140.5% | -225.6% | — | — |
| ROCE | -59.4% | -59.4% | -74.2% | -47.9% | -26.2% | -17.0% | -25.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -0.47 | -0.69 | -0.77 | -1.03 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -114979.26 | -8872.86 | — |
Net cash position: cash ($55M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 11.35 | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Quick Ratio | 11.35 | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Cash Ratio | 11.09 | 11.09 | 6.18 | 6.20 | 17.62 | 118.42 | 36.90 |
| Asset Turnover | — | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 41.1% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 41.1% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $7M | $1M | $1M | $1M | $1M | $688918 |
Binary clinical trial failure
Based on reported figures, KTTA trades at a price-to-book ratio of 0.07, suggesting that the market is valuing the company primarily as a cash-heavy shell rather than assigning meaningful enterprise value to its underlying intellectual property or clinical pipeline assets.
The extremely low P/B multiple indicates that investors are heavily discounting the potential success of the PAS-004 program. This valuation suggests that the market views the current clinical pipeline as having a high probability of failure, effectively pricing the equity below the liquidation value of its cash reserves.
According to recent SEC filings, KTTA's ROIC has remained deeply negative, fluctuating between -27.1% and -188.9% over the last ten quarters, which highlights the significant capital destruction inherent in funding early-stage biotechnology research without any offsetting revenue streams.
The persistent negative return on invested capital reflects the company's inability to generate economic value from its R&D expenditures. Investors should monitor whether the recent strategic pivot toward the MAPK/ERK pathway can eventually stabilize these returns, though current trends suggest continued capital depletion.
As reported in financial statements, the company maintains a current ratio of 35.40 as of 2026Q1, providing a significant short-term buffer that protects the firm from immediate insolvency despite the ongoing, high-burn nature of its clinical development activities.
This high liquidity position is a direct result of recent capital raises, which have temporarily insulated the company from the need for immediate dilutive financing. However, this liquidity is rapidly being consumed by operational expenses, and the current ratio will likely deteriorate significantly as clinical trial costs accelerate.
Based on the provided data, the price-to-book ratio is the most commonly misapplied metric for KTTA, as it obscures the binary nature of clinical-stage biotech assets by treating the company's cash-heavy balance sheet as a proxy for long-term operational viability.
Using P/B to value a pre-revenue biotech firm ignores the fact that the company's true value lies in the optionality of its drug pipeline, not its current cash holdings. Analysts should instead focus on the cash runway relative to clinical milestones, as the book value provides no insight into the probability-weighted success of the PAS-004 program.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KTTA stock.
Pasithea Therapeutics Corp.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Pasithea Therapeutics Corp.'s return on equity (ROE) is -58.4%. The historical average is -40.5%.
Based on historical data, Pasithea Therapeutics Corp. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.